Features associated with enhanced proliferation define lung tumors that respond to dual immune checkpoint and radiation therapy. Features associated with enhanced proliferation define lung tumors that respond to dual immune checkpoint and radiation therapy

In a randomized phase II trial, patients with early-stage non-small cell lung cancer were were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereotactic radiation. We conducted an analysis of the gene expression profiles of treatment-naive tumors from these patients and identified a 140-gene signature that was correlated with a positive response to the dual therapy. This signature showed enrichment in genes associated with cell proliferation. Overall design: RNA-seq studies of resected tumors to identify biomarkers of response in a clinical trial of immune checkpoint blockade therapy in the treatment of non-small cell lung cancer.